Brief: Royalty Pharma Reports Q4 And Full Year 2022 Results
15/02/2023 13:12
Feb 15 (Reuters) - Royalty Pharma PLC RPRX.O :
* ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2022 RESULTS
* ROYALTY PHARMA SAYS EXPECTS 2023 ADJUSTED CASH RECEIPTS
(NON-GAAP) TO BE BETWEEN $2,375 MILLION AND $2,475 MILLION
Source text for Eikon: ID:nGNX68mY5R
Further company coverage: RPRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Royalty Pharma
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Royalty Pharma falls after Novartis' cholesterol drug fails in study
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Teva's immune disorder drug meets main goal in mid-stage trial (updated)